Inside a biotech VC’s anger-driven strategy

Hello,

Welcome to Insider Healthcare. I’m healthcare editor Leah Rosenbaum, and today in healthcare news:


If you’re new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or tweet @leah_rosenbaum. Let’s get to it…


Kristina Burow, managing director at Arch Venture Partners.
Kristina Burow, managing director at . Arch Venture Partners

A top biotech VC looks for 2 factors when investing in startups that could shake up the healthcare industry

Get an inside look>>


Alloy cofounder and CEO Anne Fulenwider
Alloy cofounder and CEO Anne Fulenwider Sharon Suh/Courtesy of Alloy

Here is the 23-slide presentation a former Marie Claire editor-in-chief used to get millennial men to invest in a startup that treats menopause symptoms

See the slides now>>


Vaccine france older
A pharmacist administers the AstraZeneca COVID-19 vaccine to a patient in a pharmacy in Roubaix as part of the coronavirus disease (COVID-19) vaccination campaign in France, March 15, 2021. REUTERS/Pascal Rossignol

Vaccines cut the risk of severe COVID-19 by at least 90% in a huge real-world study of 23 million people

Check it out>>


More stories we’re reading:


-Leah